Enhanced synthesis and release of dopamine in transgenic mice with gain-of-function α6* nAChRs

Journal of Neurochemistry

Volumn 129, Issue 2, 2014, Pages 315-327

  Wang, Yuexiang ^a   Lee, Jang Won ^b   Oh, Gyeon ^a   Grady, Sharon R ^c   McIntosh, J Michael ^d   Brunzell, Darlene H ^e   Cannon, Jason R ^b   Drenan, Ryan M ^a  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

addiction; cholinergic; dopamine; nicotinic; nucleus accumbens; Parkinson's disease

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; ACETYLCHOLINE; ALPHA CONOTOXIN MII; ALPHA6BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR; DOPAMINE; DOPAMINE TRANSPORTER; HOMOVANILLIC ACID; NICOTINE; NICOTINIC RECEPTOR; NORADRENALIN; SEROTONIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINE RELEASE; GAIN OF FUNCTION MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SYNAPTOSOME; TRANSGENIC MOUSE; WESTERN BLOTTING;

ADDICTION; CHOLINERGIC; DOPAMINE; NICOTINIC; NUCLEUS ACCUMBENS; PARKINSON'S DISEASE;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; ELECTROPHYSIOLOGICAL PROCESSES; EXTRACELLULAR SPACE; MECAMYLAMINE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOSTRIATUM; NEUROTRANSMITTER AGENTS; NICOTINIC ANTAGONISTS; NUCLEUS ACCUMBENS; PATCH-CLAMP TECHNIQUES; PIPERAZINES; POLYMERASE CHAIN REACTION; RECEPTORS, NICOTINIC; REWARD;

EID: 84897138100     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12616     Document Type: Article

References (58)

1. Akopian G., Crawford C., Beal M. F., et al,. (2008) Decreased striatal dopamine release underlies increased expression of long-term synaptic potentiation at corticostriatal synapses 24 h after 3-nitropropionic-acid- induced chemical hypoxia. J. Neurosci. 28, 9585-9597.
2. Azam L., Maskos U., Changeux J. P., Dowell C. D., Christensen S., De Biasi M., and, McIntosh J. M., (2010) α-Conotoxin BuIA[T5A;P6O]: a novel ligand that discriminates between α6β4 and α6β2 nicotinic acetylcholine receptors and blocks nicotine-stimulated norepinephrine release. FASEB J. 24, 5113-5123.
3. Bobrovskaya L., Gilligan C., Bolster E. K., Flaherty J. J., Dickson P. W., and, Dunkley P. R., (2007) Sustained phosphorylation of tyrosine hydroxylase at serine 40: a novel mechanism for maintenance of catecholamine synthesis. J. Neurochem. 100, 479-489.
4. Bordia T., Grady S. R., McIntosh J. M., and, Quik M., (2007) Nigrostriatal damage preferentially decreases a subpopulation of α6β2* nAChRs in mouse, monkey, and Parkinson's disease striatum. Mol. Pharmacol. 72, 52-61.
5. Bradford M. M., (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
6. Britt J. P., and, McGehee D. S., (2008) Presynaptic opioid and nicotinic receptor modulation of dopamine overflow in the nucleus accumbens. J. Neurosci. 28, 1672-1681.
7. Cachope R., Mateo Y., Mathur B. N., Irving J., Wang H. L., Morales M., Lovinger D. M., and, Cheer J. F., (2012) Selective activation of cholinergic interneurons enhances accumbal phasic dopamine release: setting the tone for reward processing. Cell Rep. 2, 33-41.
8. Cohen B. N., Mackey E. D., Grady S. R., et al,. (2012) Nicotinic cholinergic mechanisms causing elevated dopamine release and abnormal locomotor behavior. Neuroscience 200, 31-41.
9. Corrigall W. A., Coen K. M., and, Adamson K. L., (1994) Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res. 653, 278-284.
10. Cragg S. J., (2003) Variable dopamine release probability and short-term plasticity between functional domains of the primate striatum. J. Neurosci. 23, 4378-4385.
11. Cragg S. J., Hille C. J., and, Greenfield S. A., (2000) Dopamine release and uptake dynamics within nonhuman primate striatum in vitro. J. Neurosci. 20, 8209-8217.
12. Dash B., Bhakta M., Chang Y., and, Lukas R. J., (2012) Modulation of recombinant, α2*, α3* or α4*-nicotinic acetylcholine receptor (nAChR) function by nAChR β3 subunits. J. Neurochem. 121, 349-361.
13. Doyon W. M., Thomas A. M., Ostroumov A., Dong Y., and, Dani J. A,. (2013) Potential substrates for nicotine and alcohol interactions: a focus on the mesocorticolimbic dopamine system. Biochem. Pharmacol. 86, 1181-1193.
14. Drenan R. M., and, Lester H. A., (2012) Insights into the neurobiology of the nicotinic cholinergic system and nicotine addiction from mice expressing nicotinic receptors harboring gain-of-function mutations. Pharmacol. Rev. 64, 869-879.
15. Drenan R. M., Grady S. R., Whiteaker P., et al,. (2008) In vivo activation of midbrain dopamine neurons via sensitized, high-affinity α6* nicotinic acetylcholine receptors. Neuron 60, 123-136.
16. Drenan R. M., Grady S. R., Steele A. D., McKinney S., Patzlaff N. E., McIntosh J. M., Marks M. J., Miwa J. M., and, Lester H. A., (2010) Cholinergic modulation of locomotion and striatal dopamine release is mediated by α6α4* nicotinic acetylcholine receptors. J. Neurosci. 30, 9877-9889.
17. Dunkley P. R., Bobrovskaya L., Graham M. E., von Nagy-Felsobuki E. I., and, Dickson P. W., (2004) Tyrosine hydroxylase phosphorylation: regulation and consequences. J. Neurochem. 91, 1025-1043.
18. Dwoskin L. P., Wooters T. E., Sumithran S. P., et al,. (2008) N, N'-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-evoked dopamine release and hyperactivity. J. Pharmacol. Exp. Ther. 326, 563-576.
19. Engle S. E., Broderick H. J., and, Drenan R. M,. (2012) Local application of drugs to study nicotinic acetylcholine receptor function in mouse brain slices. J. Vis. Exp. 68, e50034.
20. Engle S. E., Shih P. Y., McIntosh J. M., and, Drenan R. M., (2013) α4α6β2* Nicotinic acetylcholine receptor activation on ventral tegmental area dopamine neurons is sufficient to stimulate a depolarizing conductance and enhance surface ampa receptor function. Mol. Pharmacol. 84, 393-406.
21. Exley R., Clements M. A., Hartung H., McIntosh J. M., and, Cragg S. J., (2007) α6-Containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology 21, 21.
22. Exley R., Maubourguet N., David V., et al,. (2011) Distinct contributions of nicotinic acetylcholine receptor subunit α4 and subunit α6 to the reinforcing effects of nicotine. Proc. Natl Acad. Sci. USA 108, 7577-7582.
23. Fossom L. H., Sterling C., and, Tank A. W., (1991) Activation of tyrosine hydroxylase by nicotine in rat adrenal gland. J. Neurochem. 57, 2070-2077.
24. Frahm S., Slimak M. A., Ferrarese L., et al,. (2011) Aversion to nicotine is regulated by the balanced activity of β4 and α5 nicotinic receptor subunits in the medial habenula. Neuron 70, 522-535.
25. 3H]dopamine release from synaptosomes prepared from four mouse brain regions. J. Pharmacol. Exp. Ther. 301, 651-660.
26. Griffith L. C., and, Schulman H., (1988) The multifunctional Ca2 + /calmodulin-dependent protein kinase mediates Ca2 + -dependent phosphorylation of tyrosine hydroxylase. J. Biol. Chem. 263, 9542-9549.
27. Haycock J. W., (1990) Phosphorylation of tyrosine hydroxylase in situ at serine 8, 19, 31, and 40. J. Biol. Chem. 265, 11682-11691.
28. Haycock J. W., Ahn N. G., Cobb M. H., and, Krebs E. G., (1992) ERK1 and ERK2, two microtubule-associated protein 2 kinases, mediate the phosphorylation of tyrosine hydroxylase at serine-31 in situ. Proc. Natl Acad. Sci. USA 89, 2365-2369.
29. Hendrickson L. M., Guildford M. J., and, Tapper A. R., (2013) Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence. Front. Psychiatry 4, 29.
30. Larsson A., Jerlhag E., Svensson L., Soderpalm B., and, Engel J. A., (2004) Is an alpha-conotoxin MII-sensitive mechanism involved in the neurochemical, stimulatory, and rewarding effects of ethanol? Alcohol 34, 239-250.
31. Lof E., Olausson P., deBejczy A., Stomberg R., McIntosh J. M., Taylor J. R., and, Soderpalm B., (2007) Nicotinic acetylcholine receptors in the ventral tegmental area mediate the dopamine activating and reinforcing properties of ethanol cues. Psychopharmacology 195, 333-343.
32. Mackey E. D., Engle S. E., Kim M. R., et al,. (2012) α6* Nicotinic acetylcholine receptor expression and function in a visual salience circuit. J. Neurosci. 32, 10226-10237.
33. Mameli-Engvall M., Evrard A., Pons S., Maskos U., Svensson T. H., Changeux J. P., and, Faure P., (2006) Hierarchical control of dopamine neuron-firing patterns by nicotinic receptors. Neuron 50, 911-921.
34. McGranahan T. M., Patzlaff N. E., Grady S. R., Heinemann S. F., and, Booker T. K., (2011) α4β2 nicotinic acetylcholine receptors on dopaminergic neurons mediate nicotine reward and anxiety relief. J. Neurosci. 31, 10891-10902.
35. le Novere N., Zoli M., Lena C., Ferrari R., Picciotto M. R., Merlo-Pich E., and, Changeux J. P., (1999) Involvement of α6 nicotinic receptor subunit in nicotine-elicited locomotion, demonstrated by in vivo antisense oligonucleotide infusion. NeuroReport 10, 2497-2501.
36. Perez X. A., O'Leary K. T., Parameswaran N., McIntosh J. M., and, Quik M., (2009) Prominent role of α3/α6β2* nAChRs in regulating evoked dopamine release in primate putamen: effect of long-term nicotine treatment. Mol. Pharmacol. 75, 938-946.
37. Perez X. A., Bordia T., McIntosh J. M., and, Quik M., (2010) α6β2* and α4β2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease. Mol. Pharmacol. 78, 971-980.
38. Picciotto M. R., Zoli M., Rimondini R., Lena C., Marubio L. M., Pich E. M., Fuxe K., and, Changeux J. P., (1998) Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 391, 173-177.
39. Pons S., Fattore L., Cossu G., Tolu S., Porcu E., McIntosh J. M., Changeux J. P., Maskos U., and, Fratta W., (2008) Crucial role of α4 and α6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. J. Neurosci. 28, 12318-12327.
40. Powers M. S., Broderick H. J., Drenan R. M., and, Chester J. A., (2013) Nicotinic acetylcholine receptors containing α6 subunits contribute to alcohol reward-related behaviours. Genes Brain Behav. 12, 543-553.
41. Quik M., and, McIntosh J. M., (2006) Striatal α6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy. J. Pharmacol. Exp. Ther. 316, 481-489.
42. Quik M., and, Wonnacott S., (2011) α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease. Pharmacol. Rev. 63, 938-966.
43. Quik M., O'Leary K., and, Tanner C. M., (2008) Nicotine and Parkinson's disease: implications for therapy. Mov. Disord. 23, 1641-1652.
44. Quik M., Park K. M., Hrachova M., Mallela A., Huang L. Z., McIntosh J. M., and, Grady S. R., (2012) Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice. Neurophar-macology 63, 450-459.
45. Radcliffe P. M., Sterling C. R., and, Tank A. W., (2009) Induction of tyrosine hydroxylase mRNA by nicotine in rat midbrain is inhibited by mifepristone. J. Neurochem. 109, 1272-1284.
46. Revah F., Bertrand D., Galzi J. L., Devillers-Thiery A., Mulle C., Hussy N., Bertrand S., Ballivet M., and, Changeux J. P., (1991) Mutations in the channel domain alter desensitization of a neuronal nicotinic receptor. Nature 353, 846-849.
47. Rice M. E., and, Cragg S. J., (2004) Nicotine amplifies reward-related dopamine signals in striatum. Nat. Neurosci. 7, 583-584.
48. Salminen O., Murphy K. L., McIntosh J. M., Drago J., Marks M. J., Collins A. C., and, Grady S. R., (2004) Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol. Pharmacol. 65, 1526-1535.
49. Salminen O., Drapeau J. A., McIntosh J. M., Collins A. C., Marks M. J., and, Grady S. R., (2007) Pharmacology of α-conotoxin MII-sensitive subtypes of nicotinic acetylcholine receptors isolated by breeding of null mutant mice. Mol. Pharmacol. 71, 1563-1571.
50. Schulte A., and, Chow R. H., (1996) A simple method for insulating carbon-fiber microelectrodes using anodic electrophoretic deposition of paint. Anal. Chem. 68, 3054-3058.
51. Serova L., and, Sabban E. L., (2002) Involvement of alpha 7 nicotinic acetylcholine receptors in gene expression of dopamine biosynthetic enzymes in rat brain. J. Pharmacol. Exp. Ther. 303, 896-903.
52. Slotkin T. A., Seidler F. J., Lau C., Bartolome J., and, Schanberg S. M., (1976) Effects of chronic chlorisondamine administration on the sympatho-adrenal axis. Biochem. Pharmacol. 25, 1311-1315.
53. Smith P. K., Krohn R. I., Hermanson G. T., et al,. (1985) Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76-85.
54. Tapper A. R., McKinney S. L., Nashmi R., et al,. (2004) Nicotine activation of α4* receptors: sufficient for reward, tolerance, and sensitization. Science 306, 1029-1032.
55. Threlfell S., Lalic T., Platt N. J., Jennings K. A., Deisseroth K., and, Cragg S. J., (2012) Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons. Neuron 75, 58-64.
56. Walaas S. I., Aswad D. W., and, Greengard P., (1983) A dopamine- and cyclic AMP-regulated phosphoprotein enriched in dopamine-innervated brain regions. Nature 301, 69-71.
57. Zhang T., Zhang L., Liang Y., Siapas A. G., Zhou F. M., and, Dani J. A., (2009) Dopamine signaling differences in the nucleus accumbens and dorsal striatum exploited by nicotine. J. Neurosci. 29, 4035-4043.
58. Zhuang X., Oosting R. S., Jones S. R., Gainetdinov R. R., Miller G. W., Caron M. G., and, Hen R., (2001) Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc. Natl Acad. Sci. USA 98, 1982-1987.